Madrigal Pharmaceuticals
MDGL
116 hedge funds and large institutions have $1.01B invested in Madrigal Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 56 increasing their positions, 25 reducing their positions, and 28 closing their positions.
124% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 25
0.91% more ownership
Funds ownership: 61.42% → 62.32% (+0.91%)
14% less funds holding
Funds holding: 135 → 116 (-19)
14% less call options, than puts
Call options by funds: $30.2M | Put options by funds: $35.1M
15% less capital invested
Capital invested by funds: $1.19B → $1.01B (-$179M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
57% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$15M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$5.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$17.7M |
| 2 |
CCI
Columbus Circle Investors
|
-$6.87M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$6.45M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$6.26M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$5.32M |
MDGL Hedge Fund Activity: Q2 2019 in Review
116 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2019, worth a combined $1.01B — down 15% from $1.19B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of MDGL and 12 opened new positions — a net loss of 16 holders — while 25 trimmed existing stakes and 56 added.
The largest buyer was HealthCor Management, adding an estimated $15M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $17.7M sold.
- 116 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2019, down from 135 in Q1 2019.
- Funds reported $1.01B of Madrigal Pharmaceuticals stock for Q2 2019, down 15% quarter-over-quarter.
- 12 funds opened new Madrigal Pharmaceuticals positions in Q2 2019 and 28 closed out, a net change of -16 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2019 was HealthCor Management, an estimated $15M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2019 was Marshall Wace North America, an estimated $17.7M sold.
Based on aggregated 13F filings for Q2 2019.